Embeda® is a prescription medication that combines morphine sulfate with naltrexone hydrochloride, designed to provide pain relief while also incorporating features to deter abuse. It’s particularly aimed at patients who need continuous, long-term pain management for which alternative treatments are not sufficient. The Drug Formulary Commission of Massachusetts is currently reviewing Embeda® for potential inclusion in its list of approved medications, highlighting its status as the only abuse-deterrent formulation of extended-release morphine sulfate that has received approval from the U.S. Food and Drug Administration (FDA).
This medication was first approved by the FDA in 2009. However, it faced a setback in 2011 when it was voluntarily recalled due to stability concerns related to its manufacturing process. These issues were subsequently addressed, leading to FDA approval of a revised manufacturing process in 2013 and recognition of its abuse-deterrent properties in 2014. This made Embeda® the first among morphine extended-release products to achieve such designation.
The innovative aspect of Embeda® lies in its design: the capsules contain pellets of morphine sulfate with a core of naltrexone hydrochloride, at a ratio of 100:4.1. Morphine sulfate acts as a potent pain reliever by targeting the µ-receptor, which is primarily responsible for the drug’s analgesic effects. Naltrexone, on the other hand, is an opioid antagonist that counteracts the effects of opioids. This combination is fundamental for the drug’s abuse-deterrent feature; if the capsules are crushed, chewed, or dissolved—a common method employed by individuals seeking to abuse opioid medication—the naltrexone is released. This can reverse the effects of morphine, potentially causing withdrawal symptoms in individuals who are opioid-tolerant and increasing the risk of overdose and death.
Clinical studies have supported Embeda®’s effectiveness in pain management and its relative safety. Furthermore, research has shown that when Embeda® is manipulated to release its contents, it is “less preferred” for abuse compared to other formulations of morphine intended for extended release. This indicates its potential to deter abuse through non-oral routes, such as snorting or injecting, which are common methods for achieving a more intense high.
Despite these safeguards, Embeda®, like all opioid medications, carries significant risks. It is classified as a Schedule II controlled substance, reflecting its high potential for addiction, abuse, and misuse—even when used as prescribed. The drug also carries a black box warning, the FDA’s most stringent caution, highlighting risks including addiction, abuse, misuse, life-threatening respiratory depression (severe breathing problems), accidental ingestion, neonatal opioid withdrawal syndrome (withdrawal symptoms in newborns), and dangerous interactions with alcohol.
Offering personalised treatment programs for overcoming alcohol addiction, including detox and therapy.
Providing comprehensive care for anorexia, focusing on nutritional rehabilitation and psychological support.
Addressing various behavioral addictions through targeted therapies and support groups.
Offering therapeutic approaches to break patterns of co-dependency and build healthier relationships.
Customised treatment plans for drug addiction, including detoxification, counselling, and aftercare support.
Integrated treatment for individuals with dual diagnosis, combining addiction treatment with mental health care.
Eating Disorder Help
Specialised treatments for eating disorders, offering a blend of medical management and psychological therapy.
Addressing exercise addiction with a focus on developing balanced exercise habits and psychological well-being.
Providing effective treatment for gambling addiction, focusing on behavioral modification and financial counselling.
Gaming Addiction Help
Offering strategies and support to address gaming addiction, balancing digital engagement with real-world activities.
An opiate rehab treatment program is likely to be the most successful way to treat addiction to heroin.
Comprehensive treatment for internet addiction, promoting healthy digital habits and offline interactions.
Targeted treatment for porn addiction, focusing on the underlying issues and relationship healing.
Sex Addiction Rehab
Treating sex and love addiction with a focus on emotional regulation and developing healthy relationship skills.
Founded in 2008, WeDoRecover has evolved from an advisory service for addiction treatment into a comprehensive provider of care, following its 2019 merger with Changes Addiction Rehab in Johannesburg. Specializing in connecting patients to top-tier addiction treatment centers in the UK, South Africa, and Thailand, WeDoRecover supports individuals globally, including those from the United Arab Emirates and Europe. Accepting both South African medical aid and international health insurance, the organization facilitates access to high-quality treatment for substance and alcohol use disorders, offering individualized care that addresses the physical, mental, and social needs of patients.
Our team, led by Gareth Carter, offers empathetic and professional support, guiding you through every step of the treatment process. Whether you're in South Africa or abroad, our acceptance of various insurance plans makes quality care accessible, providing a platform for lasting recovery and a healthier future.
Finding the right rehab close to you is simple with WeDoRecover. Our network includes the finest rehab centers, ensuring personalised, quality care for your recovery needs. Let Gareth Carter and our empathetic team help guide you to a center that feels right for you, offering expert care and support. Start your healing today by choosing a rehab that's not just close to you, but also that truly cares about your loved ones recovery.